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Prognostic relevance of Wnt-inhibitory factor-1 (WIF1) and
Dickkopf-3 (DKK3) promoter methylation in human breast
cancer
Abstract
BACKGROUND: Secreted Wnt signaling antagonists have recently been described as frequent targets
of epigenetic inactivation in human tumor entities. Since gene silencing of certain Wnt antagonists was
found to be correlated with adverse patient survival in cancer, we aimed at investigating a potential
prognostic impact of the two Wnt antagonizing molecules WIF1 and DKK3 in breast cancer, which are
frequently silenced by promoter methylation in this disease. METHODS: WIF1 and DKK3 promoter
methylation were assessed by methylation-specific PCR with bisulfite-converted DNA from 19 normal
breast tissues and 150 primary breast carcinomas. Promoter methylation was interpreted in a qualitative,
binary fashion. Statistical evaluations included two-sided Fisher's exact tests, univariate log-rank tests of
Kaplan-Meier curves as well as multivariate Cox regression analyses. RESULTS: WIF1 and DKK3
promoter methylation were detected in 63.3% (95/150) and 61.3% (92/150) of breast carcinoma
samples, respectively. In normal breast tissues, WIF1 methylation was present in 0% (0/19) and DKK3
methylation in 5.3% (1/19) of samples. In breast carcinomas, WIF1 methylation was significantly
associated with methylation of DKK3 (p = 0.009). Methylation of either gene was not associated with
clinicopathological parameters, except for DKK3 methylation being associated with patient age (p =
0.007). In univariate analysis, WIF1 methylation was not associated with clinical patient outcome. In
contrast, DKK3 methylation was a prognostic factor in patient overall survival (OS) and disease-free
survival (DFS). Estimated OS rates after 10 years were 54% for patients with DKK3-methylated tumors,
in contrast to patients without DKK3 methylation in the tumor, who had a favorable 97% OS after 10
years (p < 0.001). Likewise, DFS at 10 years for patients harboring DKK3 methylation in the tumor was
58%, compared with 78% for patients with unmethylated DKK3 (p = 0.037). Multivariate analyses
revealed that DKK3 methylation was an independent prognostic factor predicting poor OS (hazard ratio
(HR): 14.4; 95% confidence interval (CI): 1.9-111.6; p = 0.011), and short DFS (HR: 2.5; 95% CI:
1.0-6.0; p = 0.047) in breast cancer. CONCLUSION: Although the Wnt antagonist genes WIF1 and
DKK3 show a very similar frequency of promoter methylation in human breast cancer, only DKK3
methylation proves as a novel prognostic marker potentially useful in the clinical management of this
disease.
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Abstract
Background: Secreted Wnt signaling antagonists have recently been described as frequent targets of epigenetic inactivation in
human tumor entities. Since gene silencing of certain Wnt antagonists was found to be correlated with adverse patient survival
in cancer, we aimed at investigating a potential prognostic impact of the two Wnt antagonizing molecules WIF1 and DKK3 in
breast cancer, which are frequently silenced by promoter methylation in this disease.
Methods: WIF1 and DKK3 promoter methylation were assessed by methylation-specific PCR with bisulfite-converted DNA
from 19 normal breast tissues and 150 primary breast carcinomas. Promoter methylation was interpreted in a qualitative, binary
fashion. Statistical evaluations included two-sided Fisher's exact tests, univariate log-rank tests of Kaplan-Meier curves as well as
multivariate Cox regression analyses.
Results: WIF1 and DKK3 promoter methylation were detected in 63.3% (95/150) and 61.3% (92/150) of breast carcinoma
samples, respectively. In normal breast tissues, WIF1 methylation was present in 0% (0/19) and DKK3 methylation in 5.3% (1/19)
of samples. In breast carcinomas, WIF1 methylation was significantly associated with methylation of DKK3 (p = 0.009).
Methylation of either gene was not associated with clinicopathological parameters, except for DKK3 methylation being
associated with patient age (p = 0.007). In univariate analysis, WIF1 methylation was not associated with clinical patient outcome.
In contrast, DKK3 methylation was a prognostic factor in patient overall survival (OS) and disease-free survival (DFS). Estimated
OS rates after 10 years were 54% for patients with DKK3-methylated tumors, in contrast to patients without DKK3 methylation
in the tumor, who had a favorable 97% OS after 10 years (p < 0.001). Likewise, DFS at 10 years for patients harboring DKK3
methylation in the tumor was 58%, compared with 78% for patients with unmethylated DKK3 (p = 0.037). Multivariate analyses
revealed that DKK3 methylation was an independent prognostic factor predicting poor OS (hazard ratio (HR): 14.4; 95%
confidence interval (CI): 1.9–111.6; p = 0.011), and short DFS (HR: 2.5; 95% CI: 1.0–6.0; p = 0.047) in breast cancer.
Conclusion: Although the Wnt antagonist genes WIF1 and DKK3 show a very similar frequency of promoter methylation in
human breast cancer, only DKK3 methylation proves as a novel prognostic marker potentially useful in the clinical management
of this disease.
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The most common epigenetic alteration in human cancer
affecting gene expression is 5'-cytosine methylation
within CpG islands in gene promoter regions [1]. Pro-
moter methylation effectively represses RNA transcription
and occurs in many genes involved in human cancer
development [2]. The majority of these affected genes are
potential or known tumor suppressor genes that are regu-
lators of different cellular pathways, such as cell cycle,
DNA repair, growth factor signaling or cell adhesion [3].
Wnt signaling is one of the central cellular pathways com-
monly disrupted in several tumor types, including breast
cancer [4,5]. Unlike colorectal cancer, evidence for genetic
alterations of Wnt pathway components in breast cancer,
such as adenomatous polyposis coli (APC) mutations, is
rare [6]. Several lines of evidence suggest that in breast
cancer the Wnt signaling pathway is disrupted predomi-
nantly through epigenetic aberrations, most of all by pro-
moter methylation of genes encoding secreted Wnt
inhibitory molecules. For instance, genes encoding
secreted frizzled-related proteins (SFRP) and Wnt-inhibi-
tory factor-1 (WIF1) were previously reported as frequent
targets of epigenetic inactivation in breast cancer [7-12].
In addition to this, we have recently shown that the puta-
tive Wnt signaling inhibitor Dickkopf-3 (DKK3) is func-
tionally inactivated by promoter methylation in more
than 60% of tumors from patients with invasive breast
cancer [13]. Besides secreted inhibitors, two studies also
reported frequent methylation of the APC gene in breast
carcinomas [14,15]. Altogether, this provides strong evi-
dence for an epigenetically disrupted and thereby acti-
vated Wnt signaling pathway in the development of
human breast cancer.
There is increasing evidence that promoter methylation of
cancer-related genes can be one of the most prevalent
molecular markers for human cancer diseases [16]. The
potential clinical applications of DNA-methylation
biomarkers may include diagnosis of neoplasm, tumor
classification, prediction of response to treatment, or
patient prognosis [17]. Methylation of particular Wnt
pathway genes has already been described as a potential
biomarker for unfavorable patient outcome in human
cancer. For instance, we have recently shown that methyl-
ation of SFRP1 as well as SFRP5 is associated with reduced
patient overall survival in breast cancer [7,10]. In contrast
to this, high-frequent methylation of SFRP2 was not prog-
nostically relevant in breast cancer [9], but was shown to
comprise a diagnostic value as a sensitive screening
marker for the stool-based detection of colorectal cancer
and premalignant colorectal lesions [18-20]. DKK3 meth-
ylation is associated with reduced DFS in acute lymphob-
lastic leukemia [21], and also with shorter OS in kidney
cancer [22] and non-small cell lung cancer [23], as well as
very recently reported with OS in gastric cancer [24].
Taken together, promoter methylation of Wnt signaling
antagonists appears to provide a rich pool of novel tumor
biomarkers in human cancer, potentially useful in the
clinical setting by helping to improve management of this
disease.
In the present study, we addressed the question to
whether promoter methylation of two Wnt antagonist
genes (WIF1 and DKK3), that were previously reported as
hypermethylated in breast cancer, provides prognostically
relevant information in this tumor entity. In univariate
and multivariate analyses we have investigated gene
methylation in a large cohort (n = 150) of invasive breast
cancer specimens. We here demonstrate for the first time
that DKK3 methylation, but not WIF1 methylation, is an
independent prognostic factor indicating poor patient
survival in human breast cancer.
Methods
Patient material
Surgically resected samples were obtained from 150 unse-
lected breast cancer patients at the Departments of Gyne-
cology at the University Hospitals of Aachen, Jena,
Regensburg and Düsseldorf in Germany from 1991 to
2005. For 19 patients, normal breast tissues were availa-
ble. In all cases, at least two-board certified pathologists
agreed on the diagnosis on breast cancer. The samples
were recruited in a non-selective, consecutive manner.
Cases were not stratified for any known pre-operative or
pathological prognostic factor. Inclusion criteria for the
study were: Female patients presenting with unilateral,
primary invasive breast cancer without individual breast
cancer history. Exclusion criteria were: neo-adjuvant
chemotherapy prior to surgery, presentation with second-
ary breast cancer, or peritumorous carcinoma in situ
present in the tumor sample. All patients gave informed
consent for retention and analysis of their tissue for
research purposes and the Institutional Review Boards of
the participating centers approved the study. Tumor his-
tology was determined according to the criteria of the
WHO (2003), while disease stage was assessed according
to UICC [25]. Histological, tumors were graded according
to Bloom and Richardson, as modified by Elston and Ellis
[26]. Hormone receptor status was assessed according to
the scoring system developed by Remmele and Stegner
[27]. For 125 patients follow-up data were available with
a median time of 64 months (range 1 to 174 months).
Patient characteristics of this cohort have been previously
described [13].
Extraction of genomic DNA
Tumor material was snap-frozen in liquid nitrogen imme-
diately after surgery. Hematoxylin/Eosin-stained sections
were prepared for assessing the percentage of tumor cells;
only samples with > 70% tumor cells were selected. A totalPage 2 of 13
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sected in a cryotom and pooled. Normal breast tissue
specimens were prepared likewise. For normal breast sam-
ples, the epithelial cell amount had to exceed 30% in
order to be selected for further preparation. Samples were
dissolved in lysis buffer followed by DNA isolation, using
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer's recommendations. The
extracted genomic DNA was finally diluted in 55 μl of Tris
buffer (10 mM; pH 7.6).
In silico promoter analysis
The WIF1 promoter, located at chromosome position
12q14.2, was investigated according to the contig
ENSG00000156076 contained in the Ensembl database
[28]. A genomic nucleotide sequence consisting of 1000
bp upstream of the annotated transcription start site (TSS)
and 293 bp downstream of the TSS (first exon) was ana-
lyzed by methprimer software [29]. Criteria for CpG
island prediction were adjusted to the definition from
Takai and Jones [30], and included an observed/expected
CpG ratio of ≥ 0.7 and a GC content of ≥ 60%. The iden-
tified CpG island proximal to the TSS was chosen for pro-
moter methylation analysis. Methylation-specific PCR
(MSP) primers were derived from a particular region
within this island, which has been analyzed for CpG
methylation by bisulfite genomic sequencing (BGS) in a
previous study [11]. The DKK3 promoter, located at chro-
mosome position 11p15.3, was investigated according to
the contig ENSG00000050165 contained in the Ensembl
database. A genomic nucleotide sequence consisting of
1000 bp upstream of the annotated TSS and 1001 bp
downstream of the TSS was analyzed by methprimer soft-
ware. The downstream region covered the first three exons
of the gene, since DKK3 was reported to be alternatively
transcribed under the control of two distinct promoters
[31]. Methprimer software identified the existence of two
distinct CpG islands, located proximal to either of the two
predicted transcription start sites. The downstream CpG
island was chosen for promoter methylation analysis,
since the shorter DKK3 transcript was shown to be more
commonly distributed in normal human tissues [31].
Bisulfite-modification and methylation-specific PCR
Approximately 1 μg of genomic DNA was bisulfite-modi-
fied using the EZ DNA Methylation Kit (Zymo Research,
Orange, CA) according to the manufacturer's recommen-
dations. The bisulfite-converted DNA was finally eluted in
20 μl of Tris buffer (10 mM; pH 7.6). Methylation-specific
PCR was performed according to Herman et al. [32]. In
short, 1 μl of modified DNA (~50 ng) was amplified using
MSP primers (see Table 1) that specifically recognized
either the unmethylated or methylated promoter
sequences after bisulfite conversion [32]. Reaction vol-
umes of 25 μl contained 1 × MSP-buffer [33], 400 nM of
each primer, and 1.25 mM of each dNTP. One drop of
mineral oil was added to each reaction tube. The PCR was
initiated as "Hot Start" PCR at 95°C and held at 80°C
before the addition of 1.25 units Taq DNA polymerase
(Promega, Madison, WI). Cycle conditions were: 95°C for
5 min, 34 cycles of 95°C for 30 sec, 55°C (58°C) for 30
sec, 72°C for 40 sec and a final extension at 72°C for 5
min. Amplification products were visualized on 3% low
range ultra agarose gel (Bio-Rad Laboratories, Hercules,
CA) containing ethidium bromide and illuminated under
ultraviolet light. Specificity of MSP primers in detecting
the promoter methylation status were demonstrated by
use of universal unmethylated and universal poly-methyl-
ated DNA as template (Epi Tect Control DNA Set; Qiagen,
Hilden, Germany). Sensitivity of the utilized primers and
cycling conditions was defined by use of a dilution series
in MSP assays, constituted of methylated DNA diluted
Table 1: Oligonucleotide primers used in the study
Sequence (5' → 3') TA
[°C]
Primer
[nM]
Product size (bp)
Methylation-specific PCR
WIF1 unmethylated Forward: GGGTGTTTTATTGGGTGTATTGT 55 400 154
Reverse: AAAAAAACTAACACAAACAAAATACAAAC
WIF1 methylated Forward: CGTTTTATTGGGCGTATCGT 55 400 145
Reverse: ACTAACGCGAACGAAATACGA
DKK3 unmethylated Forward: TTAGGGGTGGGTGGTGGGGT 58 320 126
Reverse: CTACATCTCCACTCTACACCCA
DKK3 methylated Forward: GGGCGGGCGGCGGGGC 58 320 120
Reverse: ACATCTCCGCTCTACGCCCG
TA, annealing temperature.Page 3 of 13
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and 0% methylation).
Statistical evaluations
Statistical analyses were completed using SPSS 14.0 (SPSS,
Chicago, IL). Differences were considered significant
when P-values were below 0.05. To study statistical asso-
ciations between clinicopathological factors and methyla-
tion status contingency tables and two-sided Fisher's exact
test were accomplished. In case of multiple statistical tests,
the false discovery rate controlling procedure was applied.
Survival curves were calculated using the Kaplan-Meier
method, with significance evaluated by two-sided log-
rank statistics. OS (n = 125) was measured from the day
of surgery until breast cancer-related death (n = 21) and
was censored for patients alive at last contact (n = 91), in
case of death unrelated to the tumor (n = 5) or when the
death cause was unknown (n = 8). DFS (n = 125) was
measured from surgery until local or distant relapse (n =
30) and was censored for patients alive without evidence
of relapse at the last follow-up (n = 95). A stepwise multi-
variate Cox regression model was adjusted, testing the
independent prognostic relevance of clinical/investiga-
tional factors. The limit for reverse selection procedures
was p = 0.1. Only patients for whom the status of all vari-
ables was known (n = 103) were included in the propor-
tional hazard models. The proportionality assumption for
all variables was assessed with log-negative-log survival
distribution functions. The variables tumor size (pT),
node status (pN) and histological grade (G) were dichot-
omised into less and more progressive groups (pT1-2 vs.
pT3-4; pN0 vs. pN1-3; G1-2 vs. G3).
Results
WIF1 promoter methylation in primary breast carcinomas
WIF1 promoter methylation in human breast cancer has
been previously reported by Ai et al. [11], who demon-
strated, by use of MSP, WIF1 methylation in 16 of 24
(67%) breast carcinoma samples. For three breast tumor
specimens, these MSP results had also been confirmed by
BGS. Unfortunately, in their study the WIF1 promoter
regions investigated by MSP and BGS were not matching
or overlapping, so we decided to analyze WIF1 promoter
methylation in breast cancer by MSP in the particular pro-
moter region that has been covered by BGS in the other
study (Figure 1A). Initially, a dilution series of methylated
DNA in an excess of unmethylated DNA (Epi Tect Control
DNA, bisulfite-converted) was tested by MSP. This experi-
ment determined the sensitivity of the utilized WIF1 MSP
assay to be 1.0% in the detection of methylated DNA mol-
ecules (~0.1 ng) in a background of unmethylated DNA
(~9.9 ng) (Figure 1B). Next, WIF1 promoter methylation
was determined by MSP in 150 primary breast carcinoma
specimens and also in 19 matching normal breast tissues.
In all normal breast tissues, only unmethylated WIF1 pro-
moter sequence could be detected, as indicated by exclu-
sive amplification with primers recognizing the
unmethylated DNA sequence (Figure 2). In contrast, 95 of
150 primary breast carcinomas (63.3%) revealed a meth-
ylated WIF1 promoter sequence, as indicated by amplifi-
cation with primers specific to methylated DNA (Figure
2). The remaining 55 tumor specimens (36.7%) revealed
solely unmethylated WIF1 promoter sequence. In general,
tumor samples, despite methylation, also revealed
unmethylated WIF1 promoter sequence, which is likely
due to small contaminations with stromal and endothe-
lial cells, as has also been previously described [34].
DKK3 promoter methylation in primary breast 
carcinomas
We have recently reported of frequent DKK3 promoter
methylation in human breast cancer [13]. In the respec-
tive report, we have demonstrated that DKK3 methylation
was present in 61.3% of breast cancer patients (92 of
150), whereas in 19 matching normal breast tissues only
one sample (5.3%) revealed faint methylation signals.
Methylation analysis of the human WIF1 promoterFigure 1
Methylation analysis of the human WIF1 promoter. 
(A) A 1.29 kb genomic sequence of the WIF1 promoter, ana-
lyzed by methprimer software [29], revealed the presence of 
a CpG island (blue) between relative position 604 and 1153. 
Position 1000 indicates the transcription start site (TSS, 
arrow). A region of high CpG (red vertical bars) densitiy was 
chosen for MSP analysis. The black bar indicates the MSP 
amplicon. (B) Sensitivity of the utilized MSP primers was 
determined by a dilution series of methylated DNA with 
unmethylated DNA (Epi Tect control DNA, Qiagen). At 
least 1% of methylated DNA (~0.1 ng) can be detected with 
the WIF1 MSP primers. bp, base pair marker; NTC, 'no tem-
plate control'.Page 4 of 13
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present report were physically identical with the samples
previously analyzed for DKK3 methylation. The previ-
ously analyzed DKK3 promoter region is pictured in Fig-
ure 3A. To allow a direct comparison between
methylation of these two genes, we first assayed a dilution
series of methylated DNA with unmethylated DNA by
MSP using DKK3 methylation-specific primers (see
above). This experiment determined the sensitivity of the
utilized DKK3 MSP assay to be 1.0% in the detection of
methylated DNA molecules (~0.1 ng) in a background of
unmethylated DNA (~9.9 ng) (Figure 3B), thus enabling
a subsequent correlation analysis in breast cancer employ-
ing the methylation results from both genes.
Association of WIF1 and DKK3 promoter methylation 
with clinicopathological parameters
For descriptive data analysis clinicopathological parame-
ters were correlated with the WIF1 and DKK3 promoter
methylation status. In a bivariate analysis, WIF1 methyla-
tion was not associated with patient age at diagnosis,
tumor size, lymph node status, histological grade, histo-
logical type, and estrogen or progesterone receptor status
(Table 2). DKK3 methylation was associated with
advanced patient age at diagnosis (p = 0.007), but not
associated with any other of the investigated parameters
(Table 2).
Correlation of WIF1 and DKK3 promoter methylation in 
primary breast carcinoma
In a bivariate analysis, methylation of the WIF1 promoter
was significantly associated with methylation of the DKK3
promoter (p = 0.009) (Table 2). Both gene promoters
were mutually unmethylated in tumors from 29 of 150
patients (19.3%) and mutually methylated in tumors
from 66 of 150 patients (44.0%) (Figure 4). For 55 of 150
patients (36.7%) the methylation status of the WIF1 and
DKK3 promoter differed: WIF1 methylation together with
DKK3 non-methylation was detected in 29/250 patients
(19.3%), whereas WIF1 non-methylation together with
DKK3 methylation was detected in 26 of 150 patients
(17.3%).
Association of WIF1 promoter methylation with patient 
survival
Patient OS and DFS were compared between methylated
versus unmethylated WIF1 promoter sequence by univari-
ate Kaplan-Meier analysis using log-rank statistics. In this
analysis, WIF1 methylation was not significantly associ-
WIF1 methylation in primary breast cancerFigure 2
WIF1 methylation in primary breast cancer. WIF1 
methylation analyses of primary breast cancer specimens. 
MSP was performed on bisulfite-treated DNA from breast 
cancer (T) and matching normal primary breast tissues (N). 
MSP results from three representative matched pairs and 
eight additional breast carcinomas (#) are shown. DNA 
bands in lanes labeled with U indicate MSP products amplified 
with primers recognizing the unmethylated promoter 
sequence. DNA bands in lanes labeled with M represent 
amplified MSP products with methylation-specific primers. 
Peripheral blood lymphocytes (PBL) and breast cancer cell 
line ZR75-1 served as positive controls for the methylation-
specific reaction, respectively. Water was used as template in 
the 'no template control' (NTC). Note that tumor tissue 
usually displayed a PCR product in the U-reaction as well, 
due to contaminating normal tissue (stromal cells, endothelial 
cells) present in the tumor specimens as has also been 
described by Suzuki et al. [34].
Methylation analysis of the human DKK3 promoterFigure 3
Methylation analysis of the human DKK3 promoter. 
(A) A 2.0 kb genomic sequence of the DKK3 promoter, ana-
lyzed by methprimer software [29], revealed the presence of 
two CpG islands (blue); one between relative position 834 
and 1261 and another one between position 1529 and 1917. 
Two alternative tissue-specific DKK3 transcripts have been 
described [30]. Since transcription of the shorter transcript 
is widely distributed in normal tissues, we chose the region 
of the second transcription start site (TSS, arrow) for meth-
ylation analysis. Position 1000 indicates the alternative tran-
scription start site of the longer transcript (TSS*, arrow). A 
region of high CpG (red vertical bars) densitiy within the sec-
ond CpG island was chosen for MSP analysis. (B) Sensitivity 
of the utilized MSP primers was determined by a dilution 
series of methylated DNA with unmethylated DNA (Epi Tect 
control DNA, Qiagen). At least 1% of methylated DNA (~0.1 
ng) can be detected with the DKK3 MSP primers. bp, base 
pair marker; NTC, 'no template control'.Page 5 of 13
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0.154) (Table 3), as also demonstrated by Kaplan-Meier
survival curves (Figure 5). As expected, a positive lymph
node status (pN1-3) and higher histological grade (G3)
were found to be associated with decreased OS (p = 0.002;
p = 0.001) and DFS (p < 0.001; p = 0.012).
Association of DKK3 promoter methylation with patient 
survival
Patient OS and DFS were compared between methylated
versus unmethylated DKK3 promoter sequence. In con-
trast to WIF1 methylation, DKK3 methylation was signif-
icantly associated with poor OS (5-year survival: 75% for
cases with methylated alleles vs. 97% for cases with
unmethylated alleles; 10-year survival: 54% vs. 97%; p =
0.0005; Table 3) and shorter DFS (5-year survival: 67% for
cases with methylated alleles vs. 84% for cases with
unmethylated alleles; 10-year-survival: 58% vs. 78%; p =
0.037; Table 3), as also illustrated by Kaplan-Meier sur-
vival curves (Figure 5). Based on a mean OS of 141
months (95% CI: 127–154 months) patients without
DKK3 methylation in the tumor tissue revealed much
longer mean OS (170 months, 95% CI: 163–177 months)
than patients with DKK3 methylation in the tumor tissue
Table 2: Demographic/clinicopathological parameters in relation to WIF1 and DKK3 promoter methylation
WIF1 methylation DKK3 methylation
Variable Categorization n1 No (%) Yes (%) P2 n1 No (%) Yes (%) P2
Clinicopathological factors
Age at diagnosis
<57 years 74 32 (43) 42 (57) 0.127 74 37 (50) 37 (50) 0.007
≥ 57 years 76 23 (30) 53 (70) 76 21 (28) 55 (72)
Tumor size3
pT1-pT2 129 48 (37) 81 (63) 1.000 129 52 (40) 77 (60) 0.440
pT3-pT4 18 7 (39) 11 (61) 18 5 (28) 13 (72)
Lymph node status3
pN0 72 29 (40) 43 (60) 0.606 72 32 (44) 40 (56) 0.170
pN1-pN3 71 25 (35) 46 (65) 71 23 (32) 48 (67)
Histological grade
G1-G2 88 28 (32) 60 (68) 0.170 88 31 (35) 57 (65) 0.313
G3 62 27 (44) 35 (57) 62 27 (44) 35 (57)
Histological type
IDC 122 43 (35) 79 (65) 122 45 (37) 77 (63)
lobular 19 7 (37) 12 (63) 0.296 19 7 (37) 12 (63) 0.236
other 9 5 (56) 4 (44) 9 6 (67) 3 (33)
Immunohistochemistry
Estrogen receptor
negative (IRS4 0–2) 47 21 (45) 26 (55) 0.142 47 20 (43) 27 (57) 0.467
positive (IRS 3–12) 98 31 (32) 67 (68) 98 35 (36) 63 (64)
Progesterone receptor
negative (IRS4 0–2) 51 22 (43) 29 (57) 0.206 51 21 (41) 30 (59) 0.593
positive (IRS 3–12) 94 30 (32) 64 (68) 94 34 (36) 60 (64)
WIF1 promoter
unmethylated - - - - 55 29 (53) 26 (47) 0.009
methylated - - - 95 29 (31) 66 (69)
1Only female patients with primary, unilateral invasive breast cancer were included. 2Fisher's exact test. 3According to UICC: TNM Classification of 
Malignant Tumours [25]. 4IRS, immunoreactivity score according to Remmele and Stegner [27]. Percentages may not sum to 100 due to rounding. 
IDC, invasive ductal carcinoma; n.a., not available.Page 6 of 13
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DFS of 99 months (95% CI: 90–107 months) patients
without DKK3 methylation in the tumor revealed longer
mean DFS (110 months, 95% CI: 99–122 months) than
patients with DKK3 methylation in the tumor (86
months, 95% CI: 75–97 months). Multivariate Cox
regression models were calculated and adjusted to assess
factor-related hazard risks and to test for independency of
DKK3 methylation as a prognostic factor in patient OS
and DFS. The strength of the association between DKK3
methylation and unfavourable patient outcome is pre-
sented in Table 4 and Table 5. Multivariate, DKK3 meth-
ylation in breast carcinoma represented an independent
and strong risk factor for OS (HR: 14.4; 95% CI: 1.9 –
111.6; p = 0.011; Table 4). In DFS the prognostic potency
of DKK3 methylation was weaker than in OS (HR: 2.5;
95% CI: 1.0 – 6.0; p = 0.047; Table 5).
Discussion
It was previously reported that expression of the Wnt
antagonist genes WIF1 and DKK3 is downregulated in sev-
eral tumor entities as a consequence of epigenetic DNA
modification [11,13,21,31,35,36]. WIF1 is a conserved
Wnt-binding protein that prevents Wnt ligands from
interacting with membranous frizzled receptors, thus may
inhibit activation of the Wnt/β-catenin signaling cascade
[37]. In breast, lung, prostate and bladder cancer, WIF1
expression was found to be frequently downregulated
[38], suggesting it might represent a tumor suppressor
gene. In breast cancer, this downregulation could be
attributed to hypermethylation of the WIF1 promoter
[11], as demonstrated both in breast cell lines and in pri-
mary breast carcinomas. In our study, methylation of the
WIF1 promoter was detected in 63% of invasive tumors
from breast cancer patients, thus being in good agreement
with previous results from Ai et al. [11], who reported a
frequency of 67% for WIF1 methylation in mammary
tumors. Differences may arise through different sample
sizes (n = 150 and n = 24) as well as different promoter
locations assessed in either study. DKK3 is a further
secreted inhibitor of Wnt signaling, but in contrast to
WIF1 does not sequester Wnt ligands. The actual mecha-
nism by which DKK3 acts inhibitory on Wnt pathway acti-
vation has not been identified yet, but suppression of
DKK3 increased β-catenin/T-cell factor (TCF)-dependent
gene activity in mammary cells [39], cancerous lung cells
[40] and glioma [41]. Likewise to WIF1, the DKK3 gene
was also reported as a frequent target of epigenetic inacti-
vation in numerous tumor entities, e.g. in lung cancer,
prostate cancer and leukemia [21,31,42], suggesting that
DKK3 may exert tumor suppressive functions. In a recent
report, we have demonstrated that DKK3 is frequently
inactivated in invasive breast carcinomas by promoter
methylation leading to loss of DKK3 expression [13]. This
epimutation affected 92 of 150 investigated breast cancer
patients (61%). Since these samples were identical to the
samples for which we now have determined WIF1 meth-
ylation, we were able to perform a combined analysis of
both genes' methylation in breast cancer.
In a bivariate analysis, WIF1 methylation status in breast
carcinomas was significantly associated with the DKK3
methylation status. Despite, within the cohort of carcino-
mas being affected by methylation of either the DKK3 or
WIF1 gene, a large fraction (45%) showed methylation in
one gene only. This demonstrates that in spite of a statis-
tical association between methylation of the two genes,
there is still a large fraction of breast cancer patients with
different DKK3/WIF1 methylation pattern. Therefore, it is
unlikely that methylation of both Wnt antagonist genes is
a mandatory mutual carcinogenic event. In a further cor-
relation analysis, neither of the two genes was associated
with relevant clinicopathological features, except for
DKK3 methylation being associated with advanced
patient age. Age-dependent promoter methylation has
been reported previously [43,44] and may randomly over-
lay the effects of gene-specific promoter methylation that
can lead to the development of distinct cancer subtypes.
Distribution of WIF1 and DKK3 promoter methylation in pri-mary reast carcinomasFigure 4
Distribution of WIF1 and DKK3 promoter methyla-
tion in primary breast carcinomas. Methylation status of 
either gene has been determined by MSP in the same tumors. 
Of n = 150 breast cancer patients, the larger fraction reveals 
an identical methylation status of both genes (63.3%). In the 
remaining smaller fraction (36.6%), methylation of only one 
of the two genes could be detected. In total, WIF1 methyla-
tion was significantly associated with DKK3 methylation (p = 
0.009; Fisher's exact test).Page 7 of 13
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methylation with important clinicopathological factors
like tumor size, histological grade and lymph node inva-
sion strongly suggests that methylation of either gene is an
early carcinogenic event in breast cancer development,
rather than contributing to tumor progression.
Most important, major differences between WIF1 and
DKK3 methylation arise in their association with breast
cancer patient survival. WIF1 methylation showed no sig-
nificance in clinical patient outcome in contrast to DKK3
methylation, which was tightly associated with adverse
patient OS and weaker with short DFS in our study.
Patients harboring DKK3 methylation in the tumor had a
poor prognosis (54% chance of 10-years OS) in contrast
to patients retaining an unmethylated DKK3 promoter,
who had a favorable prognosis (97% chance of 10-years
OS). This finding was supported by a multivariate Cox
Table 3: Univariate survival analysis of clinicopathological and molecular factors (log-rank test)
Variable Categorization Overall survival Disease-free survival
n1 events P2 n1 events P2
Clinicopathological factors
Age at diagnosis
<57 years 64 7 0.094 64 16 0.711
≥ 57 years 61 14 61 14
Tumor size3
pT1-pT2 107 17 0.372 107 25 0.427
pT3-pT4 16 4 16 5
Lymph node status3
pN0 54 3 0.002 54 5 <0.001
pN1-pN3 65 18 65 24
Histological grade
G1-G2 72 5 0.001 72 11 0.012
G3 53 16 53 19
Histological type
IDC 101 19 0.267 101 22 0.277
other 24 2 24 8
Immunohistochemistry
Estrogen receptor
negative (IRS4 0–2) 40 9 0.155 40 9 0.962
positive (IRS 3–12) 80 12 80 21
Progesterone receptor
negative (IRS4 0–2) 39 9 0.154 39 13 0.087
positive (IRS 3–12) 81 12 81 17
WIF1 promoter
unmethylated 47 9 0.656 47 8 0.154
methylated 78 12 78 22
DKK3 promoter
unmethylated 46 1 <0.001 46 7 0.037
methylated 79 20 79 23
1Only female patients with primary, unilateral invasive breast cancer were included. 2Log-rank test. 3According to UICC: TNM Classification of 
Malignant Tumours [25]. 4IRS, immunoreactivity score according to Remmele and Stegner [27]. IDC, invasive ductal carcinoma.Page 8 of 13
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Univariate Kaplan-Meier survival analysis of breast cancer patients in relation to WIF1 and DKK3 promoter methylationFigure 5
Univariate Kaplan-Meier survival analysis of breast cancer patients in relation to WIF1 and DKK3 promoter 
methylation. (A) Overall survival and (B) disease-free survival are not associated with WIF1 promoter methylation in human 
breast cancer. Solid lines indicate methylated WIF1 promoter; dotted lines indicate unmethylated WIF1 promoter in the tumor. 
(C) In contrast, methylation of the DKK3 promoter in tumor tissue (solid line) is significantly associated with adverse patient 
overall survival, whereas patients with an unmethylated DKK3 promoter in the tumor tissue have a very favorable clinical out-
come (dotted line) (p < 0.001). (D) In addition, DKK3-methylated tumors reveal a significant shorter time to recurrence (solid 
line), as compared to tumors harboring an unmethylated DKK3 promoter (dotted line) (p = 0.037). Vertical tick marks repre-
sent censored patients.
BMC Cancer 2009, 9:217 http://www.biomedcentral.com/1471-2407/9/217regression analysis in which DKK3-methylated patients
revealed a high risk of tumor-related death (HR: 14.4).
Hence, this parameter outperformed classical prognostic
factors in our patient cohort, i.e. high histological grade
(HR: 4.4) or a positive lymph node status (HR: 5.5).
Unproportional HRs of high impact were rarely achieved
even in studies with very large sample size numbers, nei-
ther by strong conventional factors like node status (HR:
2.4) [45] and grade (HR: 5.7) [46] nor by investigational
factors like the tissue urokinase-type plasminogen activa-
tor/inhibitor (uPA/PAI), which in case of high level
exposes patients to a five times greater risk of dying from
breast cancer [47]. In conclusion, our results demonstrate
that determination of the DKK3 methylation status may
provide valuable information to aid prognostication in
the clinical management of breast cancer patients. Nota-
bly, methylation of the DKK3 promoter was recently
shown to be prognosis relevant also in other tumor enti-
ties, such as in acute lymphoblastic leukemia, kidney can-
cer, lung cancer, and gastric cancer [21-24], pointing to a
potential clinical use of this marker in several cancer dis-
eases.
Our findings raise expectations towards translation of
such methylation markers into clinical practice. As an
example, DKK3 may be a prime candidate gene to be
incorporated into diagnostic multimarker panels, for its
aberrant methylation is specific to malignant cells in
breast cancer [13]. Preliminary results from our laboratory
revealed that DKK3 methylation can be detected with high
clinical sensitivity and specificity in blood serum of breast
cancer patients independent of tumor size and node status
(unpublished data). The presence of detectable tumor
DNA in serum is generally associated with poor prognosis
[48,49], and taken together with its marker performance
in solid breast tumor tissue, DKK3 methylation fulfils
essential prerequisites as a biomarker in a blood-borne
assay, of which we will report in a future study.
In summary, we here demonstrate that although WIF1
and DKK3 promoter methylation are similar frequent
alterations in human breast cancer, only DKK3 methyla-
tion appears to be a survival risk factor for breast cancer
patients and thus might be useful as prognostic marker in
clinical oncology helping to improve patient outcome.
Table 4: Multivariate Cox regression analysis of DKK3 promoter methylation with regard to overall survival
Multivariate analysis
Overall survival
(global model)
Multivariate analysis
Overall survival
(reverse selection procedure2)
Variable HR 95% CI1 P HR 95% CI1 P
Age at diagnosis <57 years 0 1.0 1.0
≥ 57 years 1 1.78 0.63 – 4.99 0.276 2.27 0.85 – 6.07 0.104
Tumor size pT1-2 0 1.0
pT3-4 1 0.83 0.25 – 2.78 0.766
Lymph nodes pN0 0 1.0 1.0
pN1-3 1 5.47 1.46 – 20.53 0.012 4.50 1.26 – 15.87 0.021
Histological grade G1 0 1.0 1.0
G2-G3 1 4.36 1.54 – 12.40 0.006 4.50 1.57 – 12.87 0.005
Histological type ductal 0 1.0
other 1 0.46 0.09 – 2.22 0.330
Estrogen receptor negative 0 1.0 1.0
positive 1 0.51 0.18 – 1.47 0.214 0.43 0.17 – 1.09 0.426
Progesterone receptor negative 0 1.0
positive 1 0.57 0.21 – 1.54 0.270
DKK3 promoter unmethylated 0 1.0 1.0
methylated 1 14.41 1.86 – 111.56 0.011 13.68 1.77–105.52 0.012
1Confidence interval (CI) on the estimated hazard ratio (HR). 2Only terms that remained in the model after reverse selection are listed. All 
variables were stratified binary according to Table 3.Page 10 of 13
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This study shows that the Wnt antagonist gene WIF1 is fre-
quently inactivated by promoter hypermethylation in
human breast cancer. Although WIF1 is similarly frequent
hypermethylated like the Wnt antagonist gene DKK3, and
neither gene methylation is associated with relevant clin-
icopathological factors, DKK3 methylation is an inde-
pendent prognostic factor in breast cancer patient
survival, whereas WIF1 methylation is not. These differ-
ences may reflect subtle distinctions in the biological roles
of the two related molecules in inhibiting Wnt/β-catenin
signaling.
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Table 5: Multivariate Cox regression analysis of DKK3 promoter methylation with regard to disease-free survival
Multivariate analysis
Disease-free survival
(global model)
Multivariate analysis
Disease-free survival
(reverse selection procedure2)
Variable HR 95% CI1 P HR 95% CI1 P
Age at diagnosis <57 years 0 1.0
≥ 57 years 1 0.57 0.24 – 1.33 0.191
Tumor size pT1-2 0 1.0
pT3-4 1 0.61 0.22 – 1.72 0.353
Lymph nodes pN0 0 1.0 1.0
pN1-3 1 4.24 1.50 – 11.96 0.006 4.01 1.49 – 10.81 0.006
Histological grade G1 0 1.0 1.0
G2-G3 1 2.01 0.91 – 4.43 0.086 1.93 0.88 – 4.24 0.102
Histological type IDC 0 1.0
other 1 1.04 0.42–2.62 0.929
Estrogen receptor negative 0 1.0
positive 1 2.17 0.78 – 6.03 0.137
Progesterone receptor negative 0 1.0 1.0
positive 1 0.36 0.15 – 0.88 0.025 0.53 0.25 – 1.11 0.091
DKK3 promoter unmethylated 0 1.0 1.0
methylated 1 2.46 1.01 – 5.97 0.047 2.08 0.88 – 4.88 0.094
1Confidence interval (CI) on the estimated hazard ratio (HR). 2Only terms that remained in the model after reverse selection are listed. All 
variables were stratified binary according to Table 3.Page 11 of 13
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